Activation of the anticancer drugs cyclophosphamide and ifosfamide by cytochrome P450 BM3 mutants
- 1 January 2015
- journal article
- Published by Elsevier in Toxicology Letters
- Vol. 232 (1) , 182-192
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- P450BM3(CYP102A1): connecting the dotsChemical Society Reviews, 2011
- Role of residue 87 in substrate selectivity and regioselectivity of drug-metabolizing cytochrome P450 CYP102A1 M11JBIC Journal of Biological Inorganic Chemistry, 2011
- Overexpression of Cytochrome P450 Epoxygenases Prevents Development of Hypertension in Spontaneously Hypertensive Rats by Enhancing Atrial Natriuretic PeptideThe Journal of Pharmacology and Experimental Therapeutics, 2010
- The epoxyeicosatrienoic acid-stimulated phosphorylation of EGF-R involves the activation of metalloproteinases and the release of HB-EGF in cancer cellsActa Pharmacologica Sinica, 2010
- Improvement of Cyclophosphamide Activation by CYP2B6 Mutants: From in Silico to ex VivoMolecular Pharmacology, 2008
- Application of drug metabolising mutants of cytochrome P450 BM3 (CYP102A1) as biocatalysts for the generation of reactive metabolitesChemico-Biological Interactions, 2008
- Re-engineering cytochrome P450 2B11dH for enhanced metabolism of several substrates including the anti-cancer prodrugs cyclophosphamide and ifosfamideArchives of Biochemistry and Biophysics, 2007
- Enhanced antitumor activity of P450 prodrug-based gene therapy using the low Km cyclophosphamide 4-hydroxylase P450 2B11Molecular Cancer Therapeutics, 2006
- Activation of the Anticancer Prodrugs Cyclophosphamide and Ifosfamide: Identification of Cytochrome P450 2B Enzymes and Site-Specific Mutants with Improved Enzyme KineticsMolecular Pharmacology, 2004
- Roles of key active-site residues in flavocytochrome P450 BM3Biochemical Journal, 1999